CA2468344A1 - Methods and compositions for treating lesions of the respiratory epithelium - Google Patents

Methods and compositions for treating lesions of the respiratory epithelium Download PDF

Info

Publication number
CA2468344A1
CA2468344A1 CA002468344A CA2468344A CA2468344A1 CA 2468344 A1 CA2468344 A1 CA 2468344A1 CA 002468344 A CA002468344 A CA 002468344A CA 2468344 A CA2468344 A CA 2468344A CA 2468344 A1 CA2468344 A1 CA 2468344A1
Authority
CA
Canada
Prior art keywords
composition
seq
trefoil
trefoil peptide
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002468344A
Other languages
English (en)
French (fr)
Inventor
Daniel K. Podolsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2468344A1 publication Critical patent/CA2468344A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002468344A 2001-11-28 2002-11-27 Methods and compositions for treating lesions of the respiratory epithelium Abandoned CA2468344A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33383601P 2001-11-28 2001-11-28
US60/333,836 2001-11-28
PCT/US2002/038258 WO2003045332A2 (en) 2001-11-28 2002-11-27 Methods and compositions for treating lesions of the respiratory epithelium

Publications (1)

Publication Number Publication Date
CA2468344A1 true CA2468344A1 (en) 2003-06-05

Family

ID=23304463

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002468344A Abandoned CA2468344A1 (en) 2001-11-28 2002-11-27 Methods and compositions for treating lesions of the respiratory epithelium

Country Status (8)

Country Link
US (2) US20030114384A1 (https=)
EP (1) EP1461076A4 (https=)
JP (1) JP2005532988A (https=)
CN (1) CN1617739A (https=)
AU (1) AU2002351181B2 (https=)
CA (1) CA2468344A1 (https=)
MX (1) MXPA04005053A (https=)
WO (1) WO2003045332A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525018B1 (en) 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US20030185838A1 (en) * 2001-11-28 2003-10-02 Podolsky Daniel K. Methods and compositions for treating lesions of the respiratory epithelium
US6610043B1 (en) 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
US7654998B1 (en) 1999-08-23 2010-02-02 Aeris Therapeutics, Inc. Tissue volume reduction
US20040171544A1 (en) * 2001-04-24 2004-09-02 Barker Nicholas P. Trefoil domain-containing polypeptides and uses thereof
US20060189526A1 (en) * 2002-04-24 2006-08-24 Podolsky Daniel K Compositions containing an intestinal trefoil peptide and a mucoadhesive
US20030105016A1 (en) * 2001-09-06 2003-06-05 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US7538082B2 (en) 2001-04-24 2009-05-26 The General Hospital Corporation Methods and compositions for treating oral and esophageal lesions
US20030181384A1 (en) * 2001-09-06 2003-09-25 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20030185839A1 (en) * 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
WO2003030824A2 (en) * 2001-10-05 2003-04-17 The General Hospital Corporation Methods and compositions for treating dermal lesions
WO2003078579A2 (en) * 2002-03-11 2003-09-25 Aeris Therapeutics, Inc. Compositions and methods for treating emphysema
AU2003224773B2 (en) * 2002-03-26 2010-08-26 The General Hospital Corporation Combination therapy using trefoil peptides
US20060188471A1 (en) * 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
WO2004064860A1 (en) * 2003-01-17 2004-08-05 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
AU2005231479C1 (en) * 2004-04-05 2012-03-15 Sunovion Pharmaceuticals Inc. (R,R)-formoterol in combination with other pharmacological agents
US8075771B2 (en) * 2005-02-17 2011-12-13 E. I. Du Pont De Nemours And Company Apparatus for magnetic field gradient enhanced centrifugation
US20100144646A1 (en) * 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
US20110201543A1 (en) * 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
HRP20141047T1 (hr) * 2008-08-01 2015-01-02 Eye Therapies Llc Pripravci za sužavanje krvnih žila i metode njihove uporabe
CN103096917A (zh) * 2010-06-04 2013-05-08 三叶草私人有限公司 用于治疗慢性肺病的三叶因子（tff）
CN105582526B (zh) * 2016-02-25 2020-07-17 山东睿鹰制药集团有限公司 三叶因子2在制备治疗及预防肺/支气管急性炎症疾病药物方面的应用
JP7579880B2 (ja) * 2020-03-30 2024-11-08 山東睿鷹制薬集團有限公司 新型コロナウイルス感染の治療におけるＴＦＦ２タンパク質とＩＦＮ－κタンパク質の併用の応用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4370317A (en) * 1980-09-10 1983-01-25 Novo Industri A/S Pancreatic spasmolytic polypeptide
US6221840B1 (en) * 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
US6063755A (en) * 1991-02-14 2000-05-16 The General Hospital Corporation Intestinal trefoil proteins
DE69232619T2 (de) * 1991-02-14 2002-09-12 The General Hospital Corp., Charlestown Intestinale kleeblatt-proteine
DK6893D0 (da) * 1993-01-21 1993-01-21 Novo Nordisk As Peptid
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
WO1999010377A1 (en) * 1997-08-25 1999-03-04 The General Hospital Corporation Receptor for intestinal trefoil factor
BR9913152A (pt) * 1998-08-26 2001-05-15 Smithkline Beecham Corp Terapias para tratamento de doenças pulmonares
US6372439B2 (en) * 1998-10-01 2002-04-16 James R. Goldenring Screen for gastric adenocarcinoma
CA2391594A1 (en) * 1999-12-23 2001-06-28 Human Genome Sciences, Inc. Trefoil domain-containing polynucleotides, polypeptides, and antibodies
EP1341817A2 (en) * 2000-12-08 2003-09-10 Novo Nordisk A/S Tff peptides
MXPA03009772A (es) * 2001-04-24 2004-02-23 Gen Hospital Corp Metodos y composiciones para tratar lesiones orales y del esofago.

Also Published As

Publication number Publication date
EP1461076A4 (en) 2005-03-09
EP1461076A2 (en) 2004-09-29
US20080167230A1 (en) 2008-07-10
CN1617739A (zh) 2005-05-18
US20030114384A1 (en) 2003-06-19
MXPA04005053A (es) 2004-09-10
AU2002351181B2 (en) 2008-08-07
WO2003045332A3 (en) 2003-07-24
AU2002351181A1 (en) 2003-06-10
WO2003045332A2 (en) 2003-06-05
JP2005532988A (ja) 2005-11-04

Similar Documents

Publication Publication Date Title
US20080167230A1 (en) Methods and compositions for treating or preventing lesions of the respiratory epithelium
US20090227511A1 (en) Methods and compositions for treating lesions of the respiratory epithelium
US11975005B2 (en) Treatment of respiratory diseases
EP2740487B1 (en) Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
ES3028423T3 (en) Norketotifen for use in the treatment of respiratory disorders
CN115427576B (zh) 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
CN102481284A (zh) 穿心莲内酯化合物用于治疗炎症和气道病症的用途
TW201039833A (en) Novel combinations
US20110166149A1 (en) Pteridine derivatives for treating respiratory disease
CN115427569A (zh) 下气道疾病的治疗
US20220339099A1 (en) Compositions of interleukin-1 receptor antagonist
US12440488B2 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
RU2737799C1 (ru) Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6
US20060134009A1 (en) Low dose corticosteroid powders for inhalation
Kearns et al. 88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF)
WO2024077042A2 (en) Il-1 receptor antagonist treatment for neutrophilic lung disease
WO2021211006A1 (en) Inhaled hexapeptide for treating interleukin-6 related respiratory diseases
Janson et al. 4. ACUTE ASTHMA AND COPD EXACERBATIONS
Keller et al. 91 Medical rationale for nebulisation of a novel high-concentration (100mg/mL) aqueous azithromycin inhalation solution
Ito et al. 89 Superior effects of RV568, a narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis
Ito et al. 90 Inhibitory effects of RV1088, a novel narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued